Compare BBIO & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBIO | CRL |
|---|---|---|
| Founded | 2015 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 13.1B |
| IPO Year | 2019 | 1999 |
| Metric | BBIO | CRL |
|---|---|---|
| Price | $65.53 | $293.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 12 |
| Target Price | $86.33 | ★ $198.27 |
| AVG Volume (30 Days) | ★ 2.3M | 827.6K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $502,076,000.00 | ★ $1,857,601,000.00 |
| Revenue This Year | $89.45 | N/A |
| Revenue Next Year | $73.78 | $3.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.26 | 10.48 |
| 52 Week Low | $50.68 | $145.47 |
| 52 Week High | $93.42 | $303.31 |
| Indicator | BBIO | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 28.95 | 61.22 |
| Support Level | $63.47 | $267.27 |
| Resistance Level | $70.49 | $303.31 |
| Average True Range (ATR) | 2.84 | 9.37 |
| MACD | -0.40 | 0.17 |
| Stochastic Oscillator | 7.18 | 86.35 |
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.